 |
|
Intrapatient variability of tacrolimus trough level may be not the cause, but an indirect parameter of comorbidities: Editorial on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”
Jongman Kim
Clin Mol Hepatol. 2025;31(2):589-591. Published online 2025 Jan 24 DOI: https://doi.org/10.3350/cmh.2025.0076
|
|
Citations to this article as recorded by
 Correspondence to editorial on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”
Soon Kyu Lee, Jong Young Choi
Clinical and Molecular Hepatology.2025; 31(2): e161. CrossRef
|